Haemostatix Ltd
Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients.
Industries
Nr. of Employees
small (1-50)
Patents
Products
PeproStat™ Liquid
A topical liquid haemostat applied to wounds to control bleeding during surgery, formulated as a ready-to-use solution.
HXP12 ReadyFlow™
A gel-based haemostat applied with a syringe for treating less accessible wounds, pre-filled in a ready-to-use syringe.
PeproStat™ Liquid
A topical liquid haemostat applied to wounds to control bleeding during surgery, formulated as a ready-to-use solution.
HXP12 ReadyFlow™
A gel-based haemostat applied with a syringe for treating less accessible wounds, pre-filled in a ready-to-use syringe.